MedTrace Logo

A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus

NCT02851849 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2018-01-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the change from baseline in hemoglobin A1c (HbA1c) during 12 weeks of treatment with 3 dose levels of LGD-6972 compared to placebo in subjects with Type 2 Diabetes Mellitus (T2DM)

Conditions

Interventions

DRUG

LGD-6972-5 mg

5 mg LGD-6972 QD

DRUG

LGD-6972-10 mg

10 mg LGD-6972 QD

DRUG

LGD-6972-15 mg

15 mg LGD-6972 QD

OTHER

Placebo

Placebo QD

Sponsors & Collaborators

  • Ligand Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Keith Marschke, Ph.D. · Ligand Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02851849 on ClinicalTrials.gov